A Study of ILB2109 in Patients With Advanced Solid Malignancies


Innolake Biopharm

Status and phase

Phase 1


Advanced Solid Tumor


Drug: ILB2109

Study type


Funder types




Details and patient eligibility


This is a multicenter, open-label, phase Ia study to evaluate the safety, tolerability and preliminary efficacy of ILB2109, a A2a receptor antagonist, in patients with locally advanced or metastatic solid malignancies.

Full description

This is a two-part study consists of dose escalation and dose expansion. The dose escalation part adopts a 3+3 protocol design and consists of 5 cohorts. Based on the data obtained from the escalation study, selected cohorts will be expanded to further investigate the safety and efficacy of the study drug. The escalation part consists of a single-dose cycle (Cycle 0) followed by multiple-dose cycles (Cycle 1 and above). Subjects will be assessed for safety and efficacy outcomes at pre-specified time points.


48 estimated patients




18 to 80 years old


No Healthy Volunteers

Inclusion criteria

  • Histologically or cytological confirmed, solid, malignant tumor that is refractory to standard therapy or for which no standard of care regimen currently exists;
  • At least one assessable tumor lesion according to RECIST v1.1 in dose escalation part of the study ; At least one measurable tumor lesion according to RECIST v1.1 in dose expansion part of the study;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
  • Major organ functions are normal, meets pre-specified lab requirements;
  • Females of reproductive age must have a negative serological hCG test during the screening period;
  • Subjects of reproductive age (both male and female) must agree to use contraceptive methods from signing Informed Consent to 90 days post the last dose;

Exclusion criteria

  • Has received any investigational medicinal product or other systemic anticancer treatment within 4 weeks prior to the first dose of study treatment;
  • Unable to take medication orally, or has impaired GI function;
  • Has received systemic glucocorticoids (prednisone>10 mg/ day or an equivalent dose of another drug of the same class) or other immunosuppressants within 14 days prior to the first dose of study treatment;
  • Has received live, attenuated vaccines within 4 weeks prior to the first dose of study treatment;
  • Has active infection that requires intravenous anti-infective therapy;
  • History of HIV infection, or other acquired, congenital immunodeficiency disease, or a history of organ transplantation;
  • History of serious cardiovascular and cerebrovascular diseases;
  • History of adverse effect from previous antineoplastic therapy that has not returned to CTCAE grade 5.0 ≤1;
  • Cerebral parenchymal or meningeal metastasis;
  • History of ≥ Grade 3 irAE or ≥ Grade 2 myocarditis from previous immune therapy;

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

48 participants in 1 patient group

Treatment Arm
Experimental group
There are nine escalating dose cohorts.
Drug: ILB2109

Trial contacts and locations



Central trial contact

Yan Li, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems